31 results about "Cancer susceptibility" patented technology

The present invention provides methods for determining cancer susceptibility in a human subject by identifying in a nucleic acid sample from the subject, a nucleotide occurrence of a single nucleotide polymorphism (SNP) of the STK15 gene, including the STK15 Ile31 polymorphism. The invention provides isolated polynucleotides, polypeptides, specific binding pair members, and cells useful for identifying agents that affect tumor susceptibility. Furthermore, the invention provides methods for detecting low penetrance tumor susceptibility genes.

A region on chromosome 8q24.21 has been demonstrated to play a major role in particular forms of cancer. It has been discovered that certain markers and haplotypes are indicative of a susceptibility to particular cancers, including prostate cancer. Diagnostic applications for identifying a susceptibilty to cancer using these markers and haplotypes are described.

A method for the early diagnosis, prognosis or clinical monitoring of cancer disease based on the quantitation of DNA in a plasma sample from a cancer patient, a subject with cancer susceptibility or an individual at risk of developing cancer.

The present invention relates to a rectal adenocarcinoma susceptibility prediction kit, which comprises the following components: STR-1 primer, STR-2 primer, STR-3 primer, STR-4 primer, STR-5 primer, STR-6 primer; Further, it may also include: PCR amplification reaction solution, LIZ-500 molecular weight internal standard, deionized formamide. The rectal adenocarcinoma susceptibility prediction kit of the present invention can be used for the diagnosis and susceptibility prediction of rectal adenocarcinoma. The invention also provides a rectal adenocarcinoma susceptibility prediction system.

The invention relates to a PCR primer and application of the coding sequences of human breast cancer susceptibility genes BRCA1 and BRCA2 based on NGS technology. The PCR primers of the human breast cancer susceptibility genes BRCA1 and BRCA2 coding sequences include at least one pair of capture primers, and the sequences of the forward primer and reverse primer of each pair of capture primers include specific sequences and are compatible with the described Linker sequence to which the 5' end of the specific sequence is ligated. The PCR primers and applications for amplifying the coding sequences of human breast cancer susceptibility genes BRCA1 and BRCA2 based on NGS technology, the experimental operation involved in the whole method is simple, only involves PCR reagents and primer combinations, the cost is low, and double tags are introduced at the same time Sequence adapter sequence is used to distinguish different samples, which can realize high-throughput sample sequencing detection, and can effectively provide genetic detection support for risk assessment of human breast cancer and other BRCA susceptibility genes-related hereditary tumors or targeted drugs for BRCA mutations .

Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia / BRCA pathway.

Described herein are genetic pharmacopoeia for querying for individual cancer susceptibility to available molecular targeted therapies.

The invention relates to a method for forecasting the onset age of colon cancer and a kit, which pertains to the medical biotechnology and the genetic diagnosis field. The method for forecasting colon cancer susceptibility determines the genotype of C53 gene polymorphism 1808 site (rs2737) of a subject and forecasts the colon cancer susceptibility of the subject by extracting the host cell genomeDNA. The method has the advantages that: the relevance of the C53 gene polymorphism site with the onset age of colon cancer is firstly expounded, the method for forecasting colon cancer susceptibility is provided, and the method can be used for the prevention, the auxiliary diagnosis and treatment of colon cancer, as well as the development of new drugs.